secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silexion Therapeutics Corp (SLXN)
CIK:        0002022416
Form:       8-K
Filed at:   2026-08-03T13:28:21+00:00
Accession:  0001178913-26-003761
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Silexion Therapeutics appoints Avner Lushi to audit committee after Peled resignation
--------------------------------------------------------------------------------

- Professor Amnon Peled resigned from board and audit committee effective Aug 1, 2026 for personal reasons, no disagreement.
- Avner Lushi, existing independent board member, appointed to audit committee effective Aug 1, 2026.
- Audit committee now has three independent members: Dror J. Abramov (Chair), Ruth Alon, and Avner Lushi, restoring Nasdaq compliance.
- Lushi is Managing Partner and CEO of Guangzhou Sino-Israel Bio-industry Investment Fund (GIBF).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022416/000117891326003761/0001178913-26-003761-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022416/000117891326003761/zk2635816.htm
  HTML page:      https://secwatch.observer/filing/0001178913-26-003761

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer